Camras Vision Continues History of Success of SEBIO Early Stage Competition Winners

Posted by on Aug 20, 2018 in Newsroom, SEBIO News | 0 comments

Camras Vision Continues History of Success of SEBIO Early Stage Competition Winners

Camras Vision, a North-Carolina base company developing a novel ocular implant to address refractory glaucoma, is the latest example of fundraising success among winners of Southeast BIO’s Early Stage Competition- now in its 20th year. The company recently closed on $5.7M in equity funding in a Series A round led by VCapital, InFocus Capital Partners and Triangle Venture Alliance. The company’s novel device, known as the Camras Shunt, drains aqueous humor externally, avoiding scarring within the drainage site and potential failure associated with other incisional/shunt surgeries in...

Read More

Ology Bioservices Wins $8.4 Million Defense Department Award to Produce Anti-Ebola Medical Countermeasure

Posted by on Aug 20, 2018 in Newsroom | 0 comments

ALACHUA, FL. – Ology Bioservices, Inc., a biologics contract development and manufacturing organization (CDMO), announced today that it was awarded an Other Transaction Agreement (OTA) to support the Joint Project Manager Medical Countermeasure Systems (JPM-MCS), a component of the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO CBRND) for advanced biologics manufacturing services-specifically, to manufacture an anti-Ebola monoclonal antibody (mAb). The award was made possible through collaborative funding between JPEO CBRND and the...

Read More

Lacerta Therapeutics, Inc. Closes On $30 million Investment Round

Posted by on Aug 14, 2018 in Newsroom | 0 comments

GAINESVILLE, FL. – UF Innovate | Sid Martin Biotech, the leading biotechnology incubator at the University of Florida, announces resident company Lacerta Therapeutics, Inc., has closed on a $30 million investment round. Lacerta is a clinical-stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for central nervous system and lysosomal storage diseases. Sarepta Therapeutics (NASDAQ: SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine,...

Read More

DEADLINE EXTENDED!!!

Posted by on Aug 14, 2018 in Newsroom | 0 comments

LAST OPPORTUNITY!! The deadline for completed applications is Tuesday, August 28, 2018.

Read More

Knight Therapeutics and TherapeuticsMD Announce Strategic Partnership

Posted by on Aug 3, 2018 in Newsroom | 0 comments

MONTREAL, CANADA and BOCA RATON, FL. – Knight Therapeutics Inc. (TSX: GUD) (“Knight”),a Canadian specialty pharmaceutical company, and TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that they have entered into a licensing agreement that grants Knight the rights to commercialize TX-004HR and TX-001HR in Canada and Israel. TX-004HR is TherapeuticsMD’s FDA-approved product, marketed as Imvexxy™ (estradiol vaginal inserts) in the U.S., for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual...

Read More

Biotest Pharmaceuticals Corporation Announces Acquisition of Biotest US Corporation by Grifols Shared Services North America, Inc.

Posted by on Aug 3, 2018 in Newsroom | 0 comments

BOCA RATON, FL. –  Biotest Pharmaceuticals Corporation (BPC), a wholly owned subsidiary of Biotest US Corporation (“Biotest USA“), and a leader in the collection of Source Plasma , is pleased to announce that Grifols Shared Services North America, Inc., a wholly owned subsidiary of Grifols, S.A. has completed its acquisition of Biotest USA for $286 Million in cash.  This acquisition comprises 22 Biotest plasma collection centers, 2 centers under construction and 2 centers under purchase contract as well as corporate offices located in Boca Raton, Florida and more...

Read More